학술논문
Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut.
Document Type
Article
Source
Subject
*Pharmaceutical industry
Alzheimer's disease
Language
Abstract
Pulling Back Amid growing controversy over the approval pathway, the agency is trying harder to get these drugs off the market when the required confirmatory trials aren't completed or fail to prove drugs work. (Bloomberg) -- When Exondys 51 was approved to treat Duchenne muscular dystrophy, a deadly disease that puts kids in wheelchairs by the time they are teenagers, there was no proof the drug actually slowed the disease. [Extracted from the article]